KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $4.7 billion.

  • Amgen's Cash from Operations rose 3116.77% to $4.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 billion, marking a year-over-year increase of 8087.36%. This contributed to the annual value of $11.5 billion for FY2024, which is 3563.92% up from last year.
  • Latest data reveals that Amgen reported Cash from Operations of $4.7 billion as of Q3 2025, which was up 3116.77% from $2.3 billion recorded in Q2 2025.
  • In the past 5 years, Amgen's Cash from Operations registered a high of $4.8 billion during Q4 2024, and its lowest value of $538.0 million during Q4 2023.
  • Its 5-year average for Cash from Operations is $2.5 billion, with a median of $2.4 billion in 2021.
  • Per our database at Business Quant, Amgen's Cash from Operations plummeted by 7969.04% in 2023 and then surged by 78680.3% in 2024.
  • Amgen's Cash from Operations (Quarter) stood at $2.8 billion in 2021, then decreased by 5.66% to $2.6 billion in 2022, then plummeted by 79.69% to $538.0 million in 2023, then skyrocketed by 786.8% to $4.8 billion in 2024, then dropped by 1.82% to $4.7 billion in 2025.
  • Its Cash from Operations was $4.7 billion in Q3 2025, compared to $2.3 billion in Q2 2025 and $1.4 billion in Q1 2025.